pexidartinib

Plexxikon MOA pexidartinib

Targeted Indication Status Sites link to clinicaltrials.gov

Pediatric
Neurofibromatosis
Type 1

Phase 1/2a

Bethesda, MD

NCT02390752

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Prada CE et al. Acta Neuropathol. 2013; 125; 159-68.